Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma （uHCC）.

Conditions: Hepatocellular Carcinoma Non-resectable; Hepatocellular Carcinoma Interventions: Drug: Ivonescimab （AK112，a PD-1/VEGF bispecific antibody） Sponsors: Tianjin Medical University Cancer Institute and Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials